← Evidence map

TrialAmerican journal of hematology2026

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

Antonio M Risitano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

The trial

NCT02009747

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study. | Socratic